Community/Retail

At the ASHP Midyear Clinical Meeting and Exhibition, Andrea White, PharmD, Pharmacy Administrative Resident at Texas Children's Hospital, discussed her presentation on Baxter's DoseEdge System, including the implementation process that Texas Children's Hospital underwent to adopt the new technology in their institution and assess the system's benefits.

A behind-the-scenes look at every pharmacist's new favorite television series.

The FDA has approved glycopyrrolate (Lonhala Magnair, Sunovion) inhalation solution, also known as SUN-101/eFlow, the first nebulized long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).

Seeing a doctor usually means making an appointment weeks in advance or going to a walk-in clinic, but Forward is different.

To ensure the safe infusion of high-alert medications, titrations need to be protected from harmful dosing changes, according to a poster presentation at the 2017 ASHP Midyear Clinical Meeting and Exhibition.

The understood link between diabetes and cardiovascular disease (CVD) has played a key role in shaping clinical trials on diabetes medications, according to a presentation at the American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition.

Dr. Baird said that it is important for pharmacy professionals to embrace these changes in technology, and he offered some advice for how to go about embracing the changes.

Success is 80% psychology and 20% mechanics. Here is how to speed up the path to success.

This chart provides a simple way to answer questions that pharmacists will receive this winter.

Pharmacists at Oklahoma State University Medical Center (OSUMC) are fighting infectious diseases with cutting-edge technology.

In this clip, Baxter Pharmacy Consultant Jason Demuth discusses the importance of building a master library for smart pumps.

The FDA has approved Novo Nordisk’s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Although administering intravenous (IV) medication via smart infusion pumps has led to improvements in patient safety, common errors persist with the use of these devices, according to a presentation at the American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition.

Between 10% and 20% of students in kindergarten through high school have chronic illness.

At the ASHP Midyear 2017 meeting, Amy Westmoreland, pharmacy manager and clinical pharmacist at Carilion Giles Community Hospital discusses the importance of collaboration between hospital pharmacists and physicians.

The FDA extended the approval of evolocumab (Repatha, Amgen) to include the prophylaxis of heart attacks, strokes, and coronary revascularizations in adults with established heart disease.

Current pharmacy technician members of ASHP will be automatically incorporated into the forum.

ASHP officials took time to recognize some of their own.

The medication is indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease.

Several people were honored this week at Baxter Healthcare Corporation’s Leadership Excellence Awards in Pharmacy, or LEAP, ceremony.

Drop the modifier, as it is causing a rift in the profession.

ASHP’s 2017 Midyear Clinical Meeting is set to begin, and Pharmacy Times will be on site covering it.

As professions expand their scopes of practice, it is critical to step back periodically and examine how the change has affected the profession and the individuals within the profession.

The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.

Nearly 21 million individuals with HIV had access to antiretroviral therapy (ART) in June 2017 compared to 685,000 HIV-positive patients in 2000.

Rising cancer drug costs have become inreasingly worrisome for patients and health care providers. Despite the entry of competitors in the market, treatment costs continue to climb over time, according to a study recently published by the Journal of Clinical Oncology.

The FDA has approved Indivior’s Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD).

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

With Midyear approaching, many are dreaming of finding that perfect program. Now is the time to start coming up with a game plan.

In a world where we are bombarded with various diets, what does the evidence say?